Evolving Aspects of Gram-positive Infections: Changing Bugs, Drugs and Endpoints (Not Official IDWeek Programming – Accredited by MedEDirect and supported by an unrestricted educational grant from Theravance BIopharma - See Affiliated Event Guide)
All Satellite Symposia, Presentation Theaters, and Learning Lounges preceding and following the Official Program IDWeekTM 2014 are independently organized and executed. IDWeek does not endorse or support the programming of any Symposium, Presentation Theater or Learning Lounge.
Andrew F. Shorr, MD, MPH (Program Chair)
Associate Chief, Pulmonary and Critical Care,
Washington Hospital Center
Associate Professor of Medicine,
Georgetown University Hospital
Ralph Corey, MD
Professor of Medicine
Duke University Medical Center
Durham, North Carolina
Keith A. Rodvold, PharmD, FCCP, FIDSA
Professor of Pharmacy Practice and Medicine
Colleges of Pharmacy and Medicine Co-Director, Section of Infectious Diseases Pharmacotherapy, Department of Pharmacy Practice
University of Illinois at Chicago
At the conclusion of the program, participants will be able to:
- Describe the clinical implication of recent changes in methicillin-resistant Staphylococcus aureus (MRSA) as a pathogenic organism, potential diagnostic and preventative measures and their potential impact on patient outcomes.
- Discuss the nuances associated with interpretation of antimicrobial susceptibility testing methods in order to be able to translate the results into positive clinical outcomes.
- Compare and contrast the newer anti-MRSA agents based upon efficacy, PK/PD and safety profiles across infection and patient types.
- Apply their understanding of the pathogen, antibiotics and patient factors in the treatment of Gram-positive infections including HAP/VAP, bacteremia and ABSSSI.
Accreditation and Credit Designation Statement — MedEDirect designates this educational activity for a maximum of (2.0) AMA PRA Category 1 CreditsTM.
MedEDirect is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Activity Number 0498-0000-14-008-L01-P and will award 2.0 contact hours (0.20 CEUs). Successful completion of the activity includes participating in the session, completing an activity evaluation form, and passing a post-test with a minimum score of 70%.
Agenda subject to change and was provided by:
MedEDirect; P: 973-525-1082; www.mededirect.org
Please contact Colleen McQuone directly at 850-385-2187 or email@example.com for more information. To Register: http:// www.mededmtgs.org/1063